Efficacy and Safety of Adalimumab in the Treatment of Non-infectious Uveitis: a Meta-analysis and Systematic Review

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2018 Jul 18

PMID 30013320

Citations 17

Authors

Shuai Ming

Kunpeng Xie

Huijuan He

Ya Li

Bo Lei

Affiliations

Soon will be listed here.

Abstract

Objective: To summarize updated evidences on the efficacy and safety of adalimumab (ADA) in the treatment of patients with non-infectious uveitis.

Patients And Methods: A systematic search between January 2000 and September 2017 was conducted using PubMed, Embase, and Cochrane libraries. We investigated control of inflammation, improvement of visual acuity (VA), corticosteroid-sparing effect, and adverse events (AEs) or serious adverse events.

Results: Three randomized clinical trials (RCTs) and 20 non-RCTs were included and analyzed. The pooled proportions of inflammation control were 74% (95% CI 64%-82%) and 79% (95% CI 69%-87%) in groups of ≤6- and ≥12-months follow-up durations. No significant difference was found between the two groups ( = 0.920, = 0.337). Analysis of subgroups classified by degree of being treatment-naïve for anti-TNFα agents showed the inflammation control reached a high of 87% (95% CI 80%-92%) when subjects were "almost naïve" to anti-TNFα before ADA treatment. VA was improved by three or more lines in 41.3% (52/126) eyes, and was equal to or better than the baseline in 88.8% (142/160) eyes. Corticosteroid sparing was observed in 82.0% (91/111) of the patients; among them, 48.8% (40/82) discontinued use of corticosteroid completely. Minor drug-related adverse events were reported. The treatment effects of ADA were generally consistent in the three RCTs, and ADA reduced the risk of treatment failure by 43%-75%.

Conclusion: The current review provided evidences that ADA might be a promising choice in reducing inflammatory activity, gaining VA, and sparing corticosteroid use with minor AEs when applied in treating non-infectious uveitis.

Citing Articles

Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies.

Zong Y, Miyagaki M, Yang M, Zhang J, Zou Y, Ohno-Matsui K Antibodies (Basel). 2024; 13(4).

PMID: 39449328 PMC: 11503300. DOI: 10.3390/antib13040086.

Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond.

Chauhan K, Tyagi M Front Ophthalmol (Lausanne). 2024; 4:1412930.

PMID: 39157460 PMC: 11327136. DOI: 10.3389/fopht.2024.1412930.

Uveitis in the Pediatric Population and Therapeutic Management: A Current Literature Review.

Modrzejewska M, Zdanowska O, Swistara D, Polubinski P Children (Basel). 2024; 11(7).

PMID: 39062219 PMC: 11274701. DOI: 10.3390/children11070769.

Diagnosis and Treatment of Uveitis in Children: A Summary of the Latest Data from a 5-Year Literature Review (2018-2023).

Modrzejewska M, Zdanowska O J Clin Med. 2024; 13(11).

PMID: 38892808 PMC: 11172654. DOI: 10.3390/jcm13113097.

Efficacy, retention rate and safety of adalimumab treatment in patients with non-infectious uveitis and scleritis: a real-world, retrospective, single-centre study.

Cam F, Celiker H Eye (Lond). 2023; 38(5):893-901.

PMID: 37884704 PMC: 10965934. DOI: 10.1038/s41433-023-02800-9.

References

Fotiadou C, Lazaridou E, Kemanetzi C, Kyrmanidou E, Ioannides D . Recalcitrant psoriatic uveitis and anti-tumor necrosis factor-α monoclonal antibodies: experience from a psoriasis referral center. Int J Dermatol. 2015; 54(9):1105-8. DOI: 10.1111/ijd.12744. View

Doycheva D, Zierhut M, Blumenstock G, Stuebiger N, Januschowski K, Voykov B . Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results. Br J Ophthalmol. 2014; 98(4):523-8. DOI: 10.1136/bjophthalmol-2013-303935. View

Tynjala P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V . Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008; 47(3):339-44. DOI: 10.1093/rheumatology/kem356. View

Ramanan A, Dick A, Jones A, McKay A, Williamson P, Compeyrot-Lacassagne S . Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017; 376(17):1637-1646. DOI: 10.1056/NEJMoa1614160. View

Munoz-Gallego A, Barral E, Enriquez E, Tejada P, Barcelo A, de Inocencio J . Adalimumab for the treatment of refractory noninfectious paediatric uveitis. Int Ophthalmol. 2016; 37(3):719-725. DOI: 10.1007/s10792-016-0293-5. View

Airody A, Heath G, Lightman S, Gale R . Non-Infectious Uveitis: Optimising the Therapeutic Response. Drugs. 2015; 76(1):27-39. DOI: 10.1007/s40265-015-0502-y. View

Vallet H, Seve P, Biard L, Fraison J, Bielefeld P, Perard L . Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network. Arthritis Rheumatol. 2016; 68(6):1522-30. DOI: 10.1002/art.39667. View

Nguyen Q, Merrill P, Jaffe G, Dick A, Kurup S, Sheppard J . Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016; 388(10050):1183-92. DOI: 10.1016/S0140-6736(16)31339-3. View

Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O . Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. J Autoimmun. 2015; 62:67-74. DOI: 10.1016/j.jaut.2015.06.005. View

10.

Suhler E, Lowder C, Goldstein D, Giles T, Lauer A, Kurz P . Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013; 97(4):481-6. DOI: 10.1136/bjophthalmol-2012-302292. View

11.

Nussenblatt R . The natural history of uveitis. Int Ophthalmol. 1990; 14(5-6):303-8. DOI: 10.1007/BF00163549. View

12.

Jaffe G, Dick A, Brezin A, Nguyen Q, Thorne J, Kestelyn P . Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med. 2016; 375(10):932-43. DOI: 10.1056/NEJMoa1509852. View

13.

Keaney M, LORIMER A . Auditing the implementation of SIGN (Scottish Intercollegiate Guidelines Network) clinical guidelines. Int J Health Care Qual Assur Inc Leadersh Health Serv. 2000; 12(6-7):314-7. DOI: 10.1108/09526869910297331. View

14.

Dobner B, Max R, Becker M, Heinz C, Veltrup I, Heiligenhaus A . A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol. 2012; 97(2):134-8. DOI: 10.1136/bjophthalmol-2011-301401. View

15.

Simonini G, Druce K, Cimaz R, Macfarlane G, Jones G . Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res (Hoboken). 2014; 66(7):1073-84. DOI: 10.1002/acr.22214. View

16.

Jabs D, Nussenblatt R, Rosenbaum J . Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005; 140(3):509-16. PMC: 8935739. DOI: 10.1016/j.ajo.2005.03.057. View

17.

Erckens R, Mostard R, Wijnen P, Schouten J, Drent M . Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2011; 250(5):713-20. PMC: 3332360. DOI: 10.1007/s00417-011-1844-0. View

18.

Diaz-Llopis M, Garcia-Delpech S, Salom D, Udaondo P, Hernandez-Garfella M, Bosch-Morell F . Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther. 2008; 24(3):351-61. DOI: 10.1089/jop.2007.0104. View

19.

Mercier A, Ribeiro E, Korobelnik J, Delyfer M, Rougier M . Efficacy of Anti-TNF-α Therapy for the Treatment of Non-infectious Uveitis: A Retrospective Study of 21 Patients. Ocul Immunol Inflamm. 2016; 26(3):477-484. DOI: 10.1080/09273948.2016.1236968. View

20.

Sen E, Sharma S, Hinchcliffe A, Dick A, Ramanan A . Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease--a case cohort interventional study. Rheumatology (Oxford). 2012; 51(12):2199-203. DOI: 10.1093/rheumatology/kes212. View